Table 1 Clinical features of all patients
Clinical features | N (%) | |
Surgery | No | 18 (51.4%) |
Yes | 17 (48.6%) | |
Primary tumor type | R-sided CRC | 13 (37.1%) |
L-sided CRC | 6 (17.1%) | |
Rectal | 8 (22.9%) | |
Brain | 1 (2.9%) | |
Duodenal | 2 (5.9%) | |
Endometrial | 1 (2.9%) | |
Gastric | 1 (2.9%) | |
Pancreas | 2 (5.9%) | |
Ampullary | 1 (2.9%) | |
T4 | Unable to assess | 5 (14.3%) |
No | 13 (37.1%) | |
Yes | 17 (48.6%) | |
Nodal involvement | Unable to assess | 10 (28.6%) |
No | 8 (22.9%) | |
Yes | 17 (46.8%) | |
BRAF V600E status (CRC only) | Unable to assess | 1 (3.7%) |
Wild type | 13 (48.1%) | |
Mutated | 13 (45.7%) | |
Baseline ctDNA status | Negative | 19 (54.3%) |
Positive | 16 (48.6%) | |
Cleared ctDNA (pre-pembrolizumab ctDNA(+); post-pembrolizumab ctDNA(-)) | Unable to assess | 2 (12.5%) |
Yes | 9 (56.3%) | |
No | 5 (31.3%) | |
